Cisplatin Neurotoxicity

New England Journal of Medicine

Volumn 322, Issue 2, 1990, Pages 126-127

  Mollman, Joan E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; CARBOPLATIN; CISPLATIN;

CANCER; EDITORIAL; HISTOCHEMISTRY; HUMAN; NEUROTOXICITY; PERCEPTION DISORDER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; ULTRASTRUCTURE;

EID: 0025169939     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199001113220210     Document Type: Editorial

References (16)

1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698–9.
2. Wallace HJ, Higby DJ. Phase I evaluation of cis-platinum (II) diamminedichloride (PDD) and a combination of PDD plus adriamycin. In: Connors TA, Roberts JJ, eds. Platinum coordination complexes in cancer chemotherapy. Vol. 48 of Rentchnick P, ed. Recent results in cancer research. New York: Springer-Verlag, 1974:167–77.
3. Wiltshaw E, Carr B. cis-Platinum (II) diamminedichloride: clinical experience of the Royal Marsden Hospital and Institute of Cancer Research, London. In: Connors TA, Roberts JJ, eds. Platinum coordination complexes in cancer chemotherapy. Vol. 48 of Rentchnick P, ed. Recent results in cancer research. New York: Springer-Verlag, 1974:178–82.
4. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–81.
5. Kedar A, Cohen ME, Freeman AI. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report. Cancer Treat Rep 1978; 62: 819–21.
6. Ashraf M, Scotchel PL, Krall JM, Fink EB. cis-Platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol 1983; 16: 309–18.
7. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269–75.
8. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34: 934–8.
9. Mollman JE, Hogan WM, Glover DJ, McCluskey LF. Unusual presentation of cis-platinum neuropathy. Neurology 1988; 38: 488–90.
10. Von Hoff DD, Reichert CM, Cunco R, Reddick R, Gallagher M, Rosezweig M. Demyelination of peripheral nerves associated with cis-diamminedichloroplatinum (II) (DDP) therapy. Proc Am Assoc Cancer Res ASCO 1979; 20: 91.
11. Marin Achéal, Rierson B. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol): treatment for advanced ovarian cancer. Ariz Med 1979; 36: 898–9.
12. Gastaut JL, Pellissier JF. Neuropathic en cisplatine: etude clinique, electrophysiologique et morphologique. Rev Neurol (Paris) 1985; 141: 614–26.
13. Goss-Sampson MA, MacEvilly CJ, Muller DPR. Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurologic function in the vitamin E deficient rat. J Neurol Sci 1988; 87: 25–35.
14. Xu T, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 1989; 39: 1077–83.
15. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89–94.
16. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721. Cancer 1988; 61: 2192–5.